A MOSAIC OF EVIDENCE: THE CLINICAL AND ECONOMIC BENEFITS OF CERAMIDE-INFUSED SKIN BARRIERS IN OSTOMY CARE
Author(s)
George Skountrianos, BS, MS1, Ariel Berger, MPH2, Nicola Sawalhi-Leckenby, MPH2, Gary Inglese, RN, MBA3, Paolo Pigatto, MD4.
1Sr Manager, HEOR, Hollister Incorporated, Libertyville, IL, USA, 2Evidera, Waltham, MA, USA, 3Hollister Incorporated, Libertyville, IL, USA, 4University of Milan, Milan, Italy.
1Sr Manager, HEOR, Hollister Incorporated, Libertyville, IL, USA, 2Evidera, Waltham, MA, USA, 3Hollister Incorporated, Libertyville, IL, USA, 4University of Milan, Milan, Italy.
Presentation Documents
OBJECTIVES: Peristomal skin complications (PSCs) following ostomy surgery are associated with increased healthcare resource utilization, poorer clinical outcomes, and reduced health-related quality of life. This study summarizes clinical, economic, and clinician-reported evidence evaluating a ceramide-infused barrier (CIB) compared with non-ceramide-infused ostomy skin barriers.
METHODS: A targeted narrative review synthesized evidence from multiple study designs. Key sources included the ADVOCATE adaptive randomized controlled trial assessing clinical and economic outcomes of CIB versus non-ceramide-infused barriers. Additional evidence was drawn from published cost-effectiveness analyses (CEAs) and budget impact models (BIMs). Multinational real-world product evaluations provided data on peristomal skin condition, wear time, accessory use, and patient- and clinician-reported satisfaction.
RESULTS: Across evidence sources, CIB demonstrated consistent clinical and economic benefits. In ADVOCATE (n=153), mean ostomy-related healthcare costs over 12 weeks were 14% lower with CIB than with control barriers ($223.73 vs $260.19), corresponding to an estimated annual per-patient savings of approximately $158. Patients using CIB experienced fewer PSCs (40.5% vs 55.4%) and higher PSC resolution rates among those with complications (53.1% vs 29.3%). CEAs projected that CIB use over 1 year would result in approximately 160 fewer PSCs, 350 additional quality-adjusted life-days, and $137,000 in healthcare cost savings per 1,000 patients, with CIB economically dominant versus standard barriers in most scenarios. BIMs estimated that 20% adoption could generate annual payer savings of approximately $6.6 million in the United States. Multinational product evaluations (~2,500 patients) found significant improvements in peristomal skin condition (66% of patients), increased wear time (48%), reduced accessory use (35%), along with high patient and clinician satisfaction.
CONCLUSIONS: Evidence from randomized, economic, and real-world sources indicates that ceramide-infused barriers can lead to improvements in peristomal skin outcomes, high patient- and clinician- satisfaction, and reductions in health system costs. These findings support CIB as a clinically and economically beneficial option for ostomy care.
METHODS: A targeted narrative review synthesized evidence from multiple study designs. Key sources included the ADVOCATE adaptive randomized controlled trial assessing clinical and economic outcomes of CIB versus non-ceramide-infused barriers. Additional evidence was drawn from published cost-effectiveness analyses (CEAs) and budget impact models (BIMs). Multinational real-world product evaluations provided data on peristomal skin condition, wear time, accessory use, and patient- and clinician-reported satisfaction.
RESULTS: Across evidence sources, CIB demonstrated consistent clinical and economic benefits. In ADVOCATE (n=153), mean ostomy-related healthcare costs over 12 weeks were 14% lower with CIB than with control barriers ($223.73 vs $260.19), corresponding to an estimated annual per-patient savings of approximately $158. Patients using CIB experienced fewer PSCs (40.5% vs 55.4%) and higher PSC resolution rates among those with complications (53.1% vs 29.3%). CEAs projected that CIB use over 1 year would result in approximately 160 fewer PSCs, 350 additional quality-adjusted life-days, and $137,000 in healthcare cost savings per 1,000 patients, with CIB economically dominant versus standard barriers in most scenarios. BIMs estimated that 20% adoption could generate annual payer savings of approximately $6.6 million in the United States. Multinational product evaluations (~2,500 patients) found significant improvements in peristomal skin condition (66% of patients), increased wear time (48%), reduced accessory use (35%), along with high patient and clinician satisfaction.
CONCLUSIONS: Evidence from randomized, economic, and real-world sources indicates that ceramide-infused barriers can lead to improvements in peristomal skin outcomes, high patient- and clinician- satisfaction, and reductions in health system costs. These findings support CIB as a clinically and economically beneficial option for ostomy care.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO53
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes
Disease
SDC: Gastrointestinal Disorders